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Abstract. The objective of this study was to examine the association among the duration of COPD, degree of hypoxemia,
and neurological abnormalities including cognitive functioning. Fifty-four patients with severe COPD and 24 age- and sex-
matched controls, were included in the study. All patients and controls were administered pulmonary function tests, standardized
Mini-mental State Examination (MMSE), Blessed Dementia Scale (BDS), Physical Self-maintenance Scale (PSMS), Modified
Activities of Daily Living scale (MADL), Instrumental Activities of Daily Living scale (IADL), Cornell Scale for Depression
in Dementia (CSDD), Global Deterioration Scale (GDS) and Clinical Dementia Rating (CDR). In addition, detailed physical
and neurological examinations were performed. Sixty-four percent of patients with COPD showed abnormalities in MMSE,
predominantly in recent memory, construction, attention, language, and orientation domains. Functional abnormalities were
correlated with cognitive abnormalities. Although COPD patients did not show significant depression compared to controls, 77.7%
of the patients showed subjective and objective cognitive disturbance and 72.2% of the patients were classified as questionable
or mild dementia. In conclusion, patients with COPD show significant cognitive and functional impairments that cannot be
explained just by coincidence or by depression.
Keywords: Chronic obstructive pulmonary disease (COPD), cognitive impairment, functional impairment, hypoxemia, hypercar-
bia
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a
disease state characterized by airflow limitation that is
not fully reversible. The airflow limitation is usually
both progressive and associated with an abnormal in-
flammatory response of the lungs to noxious particles
or gases, which leads to hypoxemia and hypercarbia
due to poor ratio of ventilation to perfusion in the lung
parenchyma [11].
Our first objective was to identify the neurological
disturbances, especially cognitive and functional im-
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pairment, in patients with COPD. We hypothesized that
patients with documented severe hypoxia would have
significantly more neurological problems than those
classified as mildly hypoxic. Although the age-related
decline in cognitive functioning of healthy adults is a
well-documented phenomenon, there is a strong rela-
tionship between COPD and cognitive dysfunction [19,
20,25]. Additionally, patients with COPD generally
showed a high frequency of cognitive impairment pos-
sibly related to duration and severity of hypoxemia and
affective status of patients [7,24,25]. Some studies
showed that 27% of patients with mild hypoxemia and
61% of patients with severe hypoxemia demonstrated
neuropsychological deficits [17]. Our second objective
was to investigate the association of hypoxia and the pa-
rameters of expiratory airflow limitation with cognitive
and daily functioning.
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2. Study design and patients
2.1. Subjects
This was a prospective clinical and neuropsycholog-
ical study performed with collaboration of the Depart-
ments of Chest Disease and Neurology at the Hospital
of Mersin University School of Medicine. The study
population included 54 patients with severe COPD, and
24 age- and sex-matched subjects as the control group.
Written informed consent was obtained from all sub-
jects. All participants were right-handed as indicated
by positive laterality quotients on the Edinburgh Hand-
edness Inventory [27]. Both the study and the control
subjects underwent ophthalmologic and audiologic ex-
aminations to exclude visual or hearing deficits, which
might compromise the reliability and validity of the
neuropsychological testing. Chest X-ray, pulmonary
function tests (PFT), arterialized blood sample analy-
sis, neuropsychological screening, electroencephalog-
raphy (EEG) and cranial computed tomography (CT)
were performed in all subjects.
Inclusion criteria for the study were as follows: 1)
strict diagnosis of COPD according to GOLD crite-
ria [11], 2) no presence of predicted memory or lan-
guage deficit, 3) being free of any psychotropic drugs
for at least 2 weeks prior to the study,4) being neurolog-
ically intact (no epilepsy, stroke, head injury, dementia,
toxic chemical exposure, sleep disorder, etc), 5) no his-
tory of concomitant severe or chronic medical illnesses
(hepatic failure, chronic renal failure, decompensate
diabetes mellitus etc.) 6) no history of depression and
other major psychiatric disorders (anxiety disorders,
schizophrenia, substance or alcohol abuse/dependence)
according to DSM-IV criteria [1], 7) no history of psy-
chosurgery or any other neurosurgical procedure.
Standardized pulmonary function tests were per-
formed using dry spirometer device (Sensor Medics
MPM, Yorba Linda, CA). We calculated the forced ex-
piratory volume in 1 second (FEV1), the forced vital
capacity (FVC), and FEV1/FVC ratio from maximal
expiratory maneuvers. Data were expressed as a per-
centage of the predicted standardized values according
to European Respiratory Society (ERS) criteria [23].
The acceptable recordings were obtained from each
maneuver and the highest values were used for further
analysis [2,28].
Arterial blood gas analysis was performed by using
ABL 330. PaO2, O2 saturation, pH and HCO3 were
evaluated for each patient. Patients with FEV1 levels
lower than 50% were classified as having severe or very
severe COPD according to GOLD criteria [11].
All patients received appropriate treatment for
COPD. At the time of the study, patients were receiv-
ing a standardized daily therapy including the follow-
ing medications: long acting β2-agonist (24 patients-
44.4%), long acting β2-agonist and long-acting anti-
cholinergic drugs (19 patients- 35.1%), long acting
β2-agonist combined with long-acting anti-cholinergic
drugs and theophylline (11 patients- 20.5%). None
were receiving inhaled or systemic corticosteroid ther-
apy. Blood levels of theophylline were in the thera-
peutic ranges in all patients receiving the drug. All
patients had stable COPD according to GOLD crite-
ria [11], and none of them had carbon dioxide narcosis
or encephalopathyaccording to clinical or EEG data. A
detailed history of COPD and memory deficit were in-
quired and recorded with a structured interview. Phys-
ical and neurological examinations were completed for
each subject by the same neurologist (ÖÜ).
2.2. Neuropsychological assessment
Standardized MMSE Test [9] was used to evaluate
cognitive status. This instrument explores spatial and
temporal orientation, short- and long-term verbal mem-
ory, attention, verbal attainment, and practical abilities
in 12 items and 30 questions. The correct answer to
each question is scored with 1 point (total from 0 to
30). A score less than 24 indicated a generic cognitive
dysfunction.
The Blessed Dementia Scale (BDS) [12] was de-
signed to assess quantitatively the signs of dementia
to enable comparisons with pathological changes. The
scale is divided into two: the information-memory-
concentration test and the dementia scale, which in-
corporated changes in everyday performance habits
and personality, and assessed orientation, memory and
concentration, which have been shown to differentiate
groups of demented and non-demented aged persons.
The total score lies between 0 (fully preserved capacity)
and 28 (extreme incapacity).
Cornell Depression Scale in Dementia (CSDD) [14]
is a scale for the diagnosis of depression in patients
with a dementia syndrome. The 19-item scale is rated
on a three-point score of absent, mild or intermittent
and severe with a note when the score was unavailable.
A score of 8 or more suggests significant depressive
symptoms.
Activities of Daily Living Scale is a battery to assess
the functional ability of older people in relation to ac-
C. Özge et al. / Cognitive function and COPD 123
Table 1
Demographic characteristics of the patients with COPD and healthy volunteers
Patients with COPD Controls
(n = 54) (n = 24)
Age (years) (mean ± SD) 64.6 ± 8.5 62.4 ± 8.4
Gender (Female) n (%) 8 (14.8%) 7 (29.2%)
Years of formal education (mean ± SD) 5.1 ± 4.8 6.7 ± 4.5
Actual smokers (%) 31.4 8.3
Patients with hypertension (%) 11.1 8.3
Patients with diabetes mellitus (%) 1.9 None
Patients with peripheral arterial disease (%) 1.9 None
Family history of
COPD (%) 24.1 8.3
Malignancy (%) 9.3 8.3
Stroke (%) − 12.5
Dementia (%) 7.4 4.1
Coronary artery disease (%) 11.1 20.8
tivities of daily living [21]. Three scales are as follows;
Physical Self-maintenance Scale (PSMS), Instrumen-
tal Activity of Daily Living scale (IADL), and Modi-
fied Activities of Daily Living scale (MADL). PSMS
details basic self-care tasks and its score lies between
6 (fully preserved capacity) and 30 (extreme incapac-
ity). IADL concerns more complex daily tasks and its
score lies between 8 (fully preserved capacity) and 31
(extreme incapacity). MADL comprises standardized
daily living activities and its score lies between 0 (full
preserved capacity) and 16 (extreme incapacity).
Global Deterioration Scale (GDS) [3] is a staging
instrument indicating deterioration in dementia. The
GDS is made up of detail clinical description of seven
major clinically distinguishable stages, ranging from
normal cognition (score 1) to very severe dementia
(score 7). Current validity of the GDS was demon-
strated by a highly significant correlation with other
neuropsychological tests such as the MMSE.
Clinical Dementia Rating (CDR) [5] is usually com-
pleted in the setting of a detailed knowledge of the in-
dividual patient. CDR has now become one of the gold
standards of global rating of dementia in trials of pa-
tients with Alzheimer’s disease. CDR ratings are 0 for
healthy people, 0.5 for questionable dementia, and 1, 2
or 3 for mild, moderate and severe dementia as defined
in the scale.
2.3. Electroencephalographic tests
Each subject was seated in a soundproof, light-
controlled, well ventilated recording room, while
30 minutes of resting EEG data were being collected
from the 14 monopolar electrode sites of the Inter-
national 10/20 system, referred to as Cz. Computer-
ized EEG recordings were obtained using Medelec Pro-
file 40-channel digital EEG equipment (Oxford, Eng-
land). The electrode impedance was carefully kept be-
low 5 kΩ. Hyperventilation was employed as stan-
dardized activation method. The filtering interval, fre-
quency and amplitude of the device were adjusted to
10 to 59 Hz, 30 mm/sec, and 100 μV, respectively. The
EEG results were evaluated visually.
2.4. Statistical analysis
Data were first evaluated using descriptive statistics.
Differences in clinical and neuropsychologicalparame-
ters between patients and control groups were assessed
by parametric and non-parametric statistics, as appro-
priate. Pearson and Spearman Correlation analyses
were run among clinical, spirometric and neuropsy-
chological variables in patient group, as appropriate.
In order to investigate the effect of clinical and spiro-
metric variables on the cognitive and functional perfor-
mance, linear regression analysis by Enter method was




Demographic features of the study groups are shown
in the Table 1. COPD and control subjects were statis-
tically similar with respect to gender, age and the dura-
tion of formal education. Table 1 also shows the mean
duration of COPD and some related health information
both in the personal and family history of the study
subjects.
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Table 2
Pulmonary testing results of patients with COPD
Pulmonary function test parameters Mean ± SD
Forced Expiratory Volume (FEV1) (L) 0.98 ± 0.35
Forced Expiratory Volume (FEV1) (%) 35.3 ± 11.5
Forced Vital Capacity (FVC) (L) 1.98 ± 0.88
Forced Vital Capacity (FVC) (%) 45.7 ± 10.8
FEV1/ FVC ratio 52.8 ± 16.4
Partial pressure O2 (mmHg) 47.3 ± 2.6
Partial pressure CO2 (mmHg) 44.3 ± 6.5
pH 7.36 ± 0.06
3.2. Pulmonary testing
Values shown in the Table 2 correspond to severe
or very severe airflow limitation according to GOLD
criteria. The mean PaO2 of 47.3 ± 2.6 mmHg was
below the normal range of 80 to 100 mmHg, indicating
the presence of moderate hypoxia in our sample. Con-
sistent with this finding, the mean PaCO2 of 44.3 ±
6.5 mmHg was slightly above the normal range of 35
to 45 mmHg, which indicates hypercapnea of moderate
degree.
3.3. Neurological examination
Neurological examination revealed the following:
bilateral resting tremor in 4 patients (7.4%), positive
palmomental reflex in 7 patients (12.9%), and de-
creased tendon reflexes in 2 patients (3.7%).
Five patients in the COPD group and one in the con-
trol group showed a specific fronto-temporal slow wave
pattern on EEG, especially in the left cerebral hemi-
sphere; however, none had epileptiform EEG abnor-
malities and significant amplitude asymmetry. One pa-
tient showed low amplitude changes, especially in the
frontal areas (see Fig. 1). None of the subjects revealed
encephalopathic or sleep changes during resting EEG.
Cranial CT scans without contrast were obtained for
31 of 54 participants (57.4%). None of the patients
showed important CT abnormality, except for non-
specific ischemic changes especially in the periven-
tricular regions. None of the neuroimaging examina-
tion suggested degenerative (e.g. Alzheimer disease) or
multi-infarct dementia.
4. Neuropsychological findings
Thirty-five patients with COPD (64.8%) showed
MMSE abnormalities. The mean score of MMSE was
24.6 ± 3.7 (13 to 30) in COPD patients, which was
significantly lower compared to that of healthy controls
(27.3± 1.9) (p = 0.0001). None of the control subjects
showed clinically important MMSE abnormalities. Ob-
served MMSE abnormalities were predominantly in re-
cent memory (25.9%), construction (38.8%), attention
(31.4%), language (12.9%), and orientation (24.0%)
(some examples of drawing abnormalities are shown
in Fig. 2). Five of the patients (9.2%) who reported
subjective complaints of memory and whose MMSE
scores were less than 24, showed generalized distur-
bance in all domains. The mean score of the BDS was
9.6± 6.6 (from 0 to 25), and 27 patients (50%) showed
increased BDS score (higher than 6 points, represented
by 2 standard deviation over the mean control values).
For the two patients who reported depression and ques-
tionable dementia, the results of the BDS were gener-
ally consistent with the MMSE results (see Table 3).
Patients with COPD were not significantly more de-
pressed than controls, as measured with CSDD scores
(6.2 ± 5.1 vs 4.5 ± 4.2, p = 0.130). Fourteen (25.9%
of) patients with severe COPD showed a depression
score above the cut-off value of 8 points. Five patients
out of 14 who had depression as measured with the
CSDD showed no significant cognitive impairment on
the MMSE and BDS. Depression was not associated
with cognitive impairment in these five patients.
When 2 SD over the mean scores of the controls were
accepted as abnormal (95% confidence interval), rates
of abnormal scores in functional capacity scales were
as follows: 14.8% in MADL (8 patients), 22.2% in
IADL (12 patients) and 20.3% in PSMS (11 patients).
Except for one patient who only showed a higher de-
pression score, all patients with abnormal scores on
functional capacity, also had significant degree of cog-
nitive impairment as detected by both the MMSE and
the BDS.
Staging of the dementia showed normal findings in
12 patients (22.2%) by the GDS and 15 patients (27.7%)
by the CDR. Other patients showed questionable or
mild dementia by those scales (see Table 4). One
patient who had increased GDS score and 7 patients
(12.9%) who had questionable dementia by CDR, did
not show important cognitive impairment on both the
MMSE and the BDS. Four of these patients showed
increased CSDD score but others showed no important
cognitive or functional impairment by the test battery
used.
Correlation analyses among clinical, spirometric
and neuropsychological data yielded some relation-
ships. Age was negatively correlated with CSDD score
(CC:0.33, p = 0.013) and hypoxemia correlated with
the frequency of sleep disturbances. On the other hand,
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Table 3
Results of neuropsychological and functional screening
Patients with COPD Controls p
N = 54 n = 24
MMSE 24.6 ± 3.7 27.3 ± 1.9 0.0001
BDS 9.6 ± 6.6 4.9 ± 4.5 0.001
MDLA 0.3 ± 0.8 0.04 ± 0.2 0.036
IDLA 0.72 ± 1.7 0.1 ± 0.6 0.030
PSMS 6.4 ± 1.1 6.0 ± 0.0 0.005
CSDD 6.2 ± 5.1 4.5 ± 4.2 0.130
GDS (n, %) 0.511
Stage 1 12 (22.2%) 9 (37.5%)
Stage 2 28 (51.8%) 11 (45.8%)
Stage 3 9 (16.6%) 3 (12.5%)
Stage 4 5 (9.4%) 1 (4.1%)
CDR (n, %) 0.000
Normal 15 (27.7%) 18 (75.0%)
Questionable dementia 34 (62.9%) 6 (25.0%)
Mild dementia 5 (9.2%) 0
MMSE: Mini-mental state examination test, BDS: Blessed dementia scale,
MADL: Modified activities of daily living scale, IADL: Instrumental activ-
ities of daily living scale, PSMS: Physical self- maintenance scale, CSDD:
Cornell scale for depression in dementia, GDS: Global deterioration scale
and CDR: Clinical dementia rating.
Fig. 1. The low amplitude pattern of EEG during resting state in a patient with severe COPD.
hypercarbia was correlated with cognitive impairment
(BDS score), functional impairment (IADL score), de-
pressive mood (CSDD), clinical stage of cognitive dis-
turbance (CDR) and the frequency of sleep disturbances
(see Table 4). Among spirometric variables, FEV1
(%) was correlated with MMSE, MADL and PSMS
scores. FVC (%) was correlated with general cogni-
tive impairment (MMSE). FEV1/FVC was correlated
with the cognitive scores on both the MMSE and the
BDS. Although none of these correlations were signifi-
cant after applying the Bonferroni correction for multi-
ple comparisons, there were significantly more correla-
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Fig. 2. Some examples of the drawings of one healthy control (a) and patients with COPD (b and c).
tions with an alpha level of p < 0.05 than would be ex-
pected by chance (chi square = 5.7; p = 0.017). There
were significant correlations between MMSE and other
tests used in the study, even after applying the Bon-
ferroni correction for multiple comparisons [i.e. BDS
(CC:0.80, p < 0.001), MADL (CC:0.46, p < 0.001),
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Table 4
Correlations between neurological dysfunctions and pulmonary function tests
PaO2 PaCO2 pH FEV1 (%) FVC (%) FEV1/FVC
MMSE − − CC:0.33 CC:0.33 CC:-0.14 CC:-0.11
p = 0.01 p = 0.005 P = 0.02 p = 0.03
BDS − CC:0.28 CC:-0.27 − − CC:0.19
p = 0.03 p = 0.04 p = 0.05
MADL − − − CC:-0.72 − −
p = 0.01
IADL − CC:0.30 − − − −
p = 0.02
PSMS − − − CC:-0.11 − −
p = 0.01
CSDD − CC:0.33 CC:-.28 − − −
p = 0.02 p = 0.04
GDS − − CC:-.28 − − −
p = 0.04
CDR − CC:0.30 − − − −
p = 0.02
Sleep disorder CC:0.50 CC:0.47 − − − −
p = 0.008 p = 0.006
MMSE: Mini-mental state examination test, BDS: Blessed dementia scale, MADL: Modified
activities of daily living scale, IADL: Instrumental activities of daily living scale, PSMS: Physical
self- maintenance scale, CSDD: Cornell scale for depression in dementia, GDS: Global deterioration
scale and CDR: Clinical dementia rating. CC: Correlation coefficient.
IADL (CC:0.47, p < 0.001), PSMS (CC:0.46, p <
0.001), GDS (CC:0.62, p < 0.001) and CDR (CC:0.72,
p < 0.001)].
When the cognitive and functional scores were en-
tered as independent variables, and spirometric and ba-
sic clinical parameters as dependent variables, the re-
sults of the linear regression analysis showed a signif-
icant effect of formal education years on the MMSE
(p = 0.001), BDS (p = 0.001), MDL (p = 0.039),
IADL (p = 0.028), CSDD (p = 0.013) and CDR (p =
0.001) scores. Only the FEV1/FVC ratio showed a sig-
nificant effect on the CSDD score (p = 0.030) in this
model.
5. Discussion
This prospective clinical and neuropsychological
study showed an increased frequency of cognitive and
functional impairments in patients with severe COPD.
These results indicate a possible effect of chronic hy-
poxemia on cognitive function and functional capac-
ity. Cognitive and functional impairments were cor-
related with hypercarbia and expiratory airflow limita-
tion. Our results might explain the decreased quality of
life and increased cognitive disturbances in these sub-
jects. To our knowledge, this is the first study about the
effects of chronic hypoxemia on the cognitive and func-
tional performance of patients with moderate to severe
COPD. Results of this study suggest that the patients
with COPD show significant cognitive and functional
impairment.
Our results are consistent with previous studies [13,
15]. Stuss et al. [7] and Grant et al. [17] found a
strong relationship among current neuropsychological
measures, decreased oxygen partial pressure (PaO2),
and increased carbon dioxide partial pressure (PaCO2).
Memory dysfunction related to hypoxia is perhaps due
to damage to the limbic memory region [7]. Another
important study showed diffuse mental deterioration in
COPD population, with particular impairment of higher
cortical functions. Verbal performance and semantic
memory were affected more than other cognitive do-
mains [16]. We showed an increased frequency of im-
portant disturbances in recent memory, construction,
attention, language, and orientation, complementing
previous reports [7,16,17].
There are three possible anatomic/pathologic bases
for the attention disorder noted in this sample. First,
prolonged oxygen deprivation might result in a chronic
state that would resemble the effects of acute depriva-
tion as demonstrated in laboratory research. Second,
the hypercapnea may produce a chronic sleepiness, af-
fecting attention performance. And third, prolonged
oxygen deprivation may lead to more permanent dif-
fuse brain damage, affecting general attention capacity.
Alternatively, there may be more direct involvement
of “frontal system”, perhaps implicating anterior atten-
tional systems [6]. A suggestive comprehensive study
by Incalzi et al. [26] compared the neuropsychologi-
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cal and cerebral perfusion performance of moderately
or severely hypoxemic COPD patients to patients with
Alzheimer Disease (AD). They reported that, opposite
to the expected, cognitive scores of patients with COPD
were lower than patients with AD. Authors concluded
that anterior cerebral hypoperfusion and selected neu-
ropsychologicaldysfunctions characterized hypoxemic
COPD patients could herald frontal-type cognitive de-
cline with the worsening of the hypoxemia.
Stuss et al. [6] hypothesized that significant impair-
ments in anterograde memory deficit might be due to
the sensitivity of the hippocampal or general limbic
memory region to hypoxia [30]. Also, it was reported
that both defective retrieval and inaccurate recognition
affect verbal memory of COPD patients [25]. As op-
posed to these results, we did not find a significant
relationship between cognitive disturbance and severe
hypoxemia but a significant relationship between cog-
nitive impairment and decreased FEV% levels. These
contrasting results might be explained by differences
in inclusion criteria and demographic features of the
patients. We think that FEV1% levels are more infor-
mative than PaO2 levels for the purpose of evaluating
chronic central nervous system effects of hypoxemia in
patients with severe COPD.
Some authors observed that physiological, func-
tional, and psychological consequences of COPD are
only weakly related to each other [4,22]. Older in-
dividuals who have COPD may be affected in three
ways that are relevant to cognitive functioning. They
may experience age-related declines in blood flow,
disease-related decline in arterial oxygen content, and
both age- and disease-related decline in physical ac-
tivity [18]. The combination of three factors may af-
fect cognitive and functional capacity, especially at ad-
vanced stages of the disease. Perfusion studies show
that chronic hypoxemia and expiratory airflow lim-
itations are associated with widespread reduction in
cerebral blood flow. Frontal and subcortical areas are
most affected. Like patients with Alzheimer’s dis-
ease, patients with advanced COPD were found to ex-
perience a high prevalence of forgetfulness due to re-
trieval deficits and impaired executive functions, prob-
ably because of the worsening of frontal and/or sub-
cortical metabolism [26]. Although our study did not
include a perfusional test, the results of neurological
(tremor, palmo-mental reflexes, etc.) and neuropsycho-
logical examination (orientation, attention, construc-
tion deficit, etc.) highly suggested a possible dysfunc-
tion of frontal and subcortical circuits. EEG and CT
examinations of some patients also supported this hy-
pothesis. In addition to cognitive dysfunction, detected
functional impairment in daily living activities in our
patients were possibly related with these anatomical
correlations.
Activity of left frontal area is highly involved in the
regulation of attention and verbal production, and is
correlated with the average cognitive performance, as
reflected by the number of correctly performed cogni-
tive tasks. Some reports pointed to a high prevalence of
frontal type behavioral and cognitive problems in ad-
vanced COPD [16]. In this study, we investigated only
severe or very severe COPD patients and determined
an important degree of cognitive impairment especially
in the areas of frontal dysfunction, particularly of the
left side. Left frontal dysfunction might also account
for the high prevalence of depression observed in this
group of patients.
As previously demonstrated by Incalzi et al. [25],
a close parallelism exists between cognitive decline
and development of depressive symptoms in patients
with COPD. The combination of cognitive and affec-
tive symptoms is quite common in geriatric popula-
tions. Patients with organic dementia frequently also
become depressed, and primarily depressed patients
show cognitive changes severe enough to be referred
as pseudodementia. Although it was not the primary
aim of this study, we diagnosed 5 patients (9.2%) with
pseudodementia and others (16.6%) with a disturbance
of affective status. Discriminant analysis did not show
any specific cognitive impairment related to depressive
symptoms in patients with severe COPD. Considering
the patients who had cognitive impairment without de-
pression (26 patients, 48.1%), we think that our results
of cognitive and functional impairment could not be
explained just by depression of chronic hypoxemia and
it might be related with other mechanisms explained
above.
Which factor is the most important in the occur-
rence of cognitive or functional disturbances in patients
with severe COPD? Some authors suggested that the
duration of COPD rather than the actual severity of
chronic respiratory failure accounts for cognitive dete-
rioration [24]. In this study, correlation and regression
analysis results showed an important relationship be-
tween the cognitive impairments and the airflow lim-
itation parameters. Some previous reports partly sug-
gested these findings [10,18] and also pointed out a spe-
cial relationship between the pulmonary function tests
(i.e: FEV1 %) values and working memory span. The
sensitivity of these functional and cognitive domains to
hypoxia was predicted based on pathologic consider-
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ations. Previously published results have varied from
virtually no correlation between various measures of
hypoxia and neuropsychological functioning [29] to
low or modest but reliable correlations [8,13]. With
the exception of Hupper’s study [10], who found cor-
relations of 0.75 to 0.82 with memory, the statistical
relationships reported between cognitive functioning
and hypoxia has been surprisingly low. Our study sug-
gested the importance of poor airway parameters and
co-morbid affective problems both on the cognitive and
functional impairments in patients with moderate or
severe COPD.
The strenghts of this study are: (1) prospective clin-
ical and neuropsychological study design, (2) detailed
neurological examination, EEG and neuroimaging of
the patients with cognitive or other neurological com-
plaints, (3) evaluation of both cognitive and functional
capacity.
Basic limitations of the present study are as fol-
lows: (1) study design that did not evaluate longitudi-
nal changes in the disease and cognitive disturbances,
(2) lack of perfusion study of the brain, (3) lack of
polysomnographic records of the patients in order to de-
termine associated sleep disturbances. However, these
limitations do not weaken the main message from the
present study: Cognitive and functional decline fre-
quently occurs in patients with severe COPD and are
highly prevalent in subjects, especially who have low
education, severe bronchial obstruction, moderate hy-
percarbia rather than hypoxemia, previous problems in
daily living activities, and coexisting depressive symp-
toms. These data are important in the planning of future
management and social strategies for these patients.
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